Department of Radiology and the Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Nucl Med Biol. 2013 Jan;40(1):3-14. doi: 10.1016/j.nucmedbio.2012.08.004. Epub 2012 Sep 19.
The advent of antibody-based cancer therapeutics has led to the concomitant rise in the development of companion diagnostics for these therapies, particularly nuclear imaging agents. A number of radioisotopes have been employed for antibody-based PET and SPECT imaging, notably ⁶⁴Cu, ¹²⁴I, ¹¹¹In, and (99m)Tc; in recent years, however, the field has increasingly focused on ⁸⁹Zr, a radiometal with near ideal physical and chemical properties for immunoPET imaging. In the review at hand, we seek to provide a comprehensive portrait of the current state of ⁸⁹Zr radiochemical and imaging research, including work into the production and purification of the isotope, the synthesis of new chelators, the development of new bioconjugation strategies, the creation of novel ⁸⁹Zr-based agents for preclinical imaging studies, and the translation of ⁸⁹Zr-labeled radiopharmaceuticals to the clinic. Particular attention will also be dedicated to emerging trends in the field, ⁸⁹Zr-based imaging applications using vectors other than antibodies, the comparative advantages and limitations of ⁸⁹Zr-based imaging compared to that with other isotopes, and areas that would benefit from more extensive investigation. At bottom, it is hoped that this review will provide both the experienced investigator and new scientist with a full and critical overview of this exciting and fast-developing field.
抗体类癌症治疗药物的出现促使与之相关的伴随诊断技术得到了发展，特别是核医学成像试剂。许多放射性同位素已被应用于抗体类正电子发射断层扫描（PET）和单光子发射计算机断层扫描（SPECT）成像，特别是 ⁶⁴Cu、¹²⁴I、¹¹¹In 和 (99m)Tc；然而，近年来该领域越来越关注 ⁸⁹Zr，这是一种放射性金属，具有用于免疫 PET 成像的理想物理和化学特性。在本综述中，我们旨在全面描述 ⁸⁹Zr 放射性化学和成像研究的现状，包括同位素的生产和纯化工作、新型螯合剂的合成、新的生物偶联策略的开发、新型 ⁸⁹Zr 基前临床成像研究试剂的创建以及 ⁸⁹Zr 标记放射性药物向临床的转化。还将特别关注该领域的新兴趋势，包括使用除抗体以外的载体进行 ⁸⁹Zr 成像应用、与其他同位素相比 ⁸⁹Zr 成像的比较优势和局限性，以及需要更广泛研究的领域。从根本上说，希望本综述能为经验丰富的研究人员和新科学家提供对这一令人兴奋且快速发展的领域的全面、批判性概述。
